Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials. (29th January 2019)

• Record Type: Journal Article
• Authors: van Eijk, Ruben P.A.; Westeneng, Henk-Jan; Nikolakopoulos, Stavros; Verhagen, Iris E.; van Es, Michael A.; Eijkemans, Marinus J.C.; van den Berg, Leonard H.
• Is Part Of: Neurology. Volume 92:Number 5(2019)
• Publication Date: 2019-01-29
• Subjects: Neurology -- Periodicals; Neurology -- Periodicals; Neurologie -- Périodiques; 616.8
• DOI: 10.1212/WNL.0000000000006855
• Languages: English
• ISSNs: 0028-3878

Abstract

Abstract : Objective: To assess the effect of eligibility criteria on exclusion rates, generalizability, and outcome heterogeneity in amyotrophic lateral sclerosis (ALS) clinical trials and to assess the value of a risk-based inclusion criterion. Methods: A literature search was performed to summarize the eligibility criteria of clinical trials. The extracted criteria were applied to an incidence cohort of 2, 904 consecutive patients with ALS to quantify their effects on generalizability and outcome heterogeneity. We evaluated the effect of a risk-based selection approach on trial design using a personalized survival prediction model. Results: We identified 38 trials. A large variability exists between trials in all patient characteristics for enrolled patients ( p < 0.001), except for the proportion of men ( p = 0.21). Exclusion rates varied widely (from 14% to 95%; mean 59.8%; 95% confidence interval 52.6%–66.7%). Stratification of the eligible populations into prognostic subgroups showed that eligibility criteria lead to exclusion of patients in all prognostic groups. Eligibility criteria neither reduce heterogeneity in survival time (from 22.0 to 20.5 months, p = 0.09) nor affect between-patient variability in functional decline (from 0.62 to 0.65, p = 0.25). In none of the 38 trials were the eligibility criteria found to be more efficient than the prediction model in optimizing sample size and eligibility rate. Conclusions: The majority of patients with ALS are excluded from trial participation, which questions the generalizability of trial results. Eligibility criteria only minimally improve homogeneity in trial endpoints. An individualized risk-based criterion could be used to balance the gains in trial design and loss in generalizability.